email article
A widely used arthritis drug reduced the rate of acute graft-versus-host disease (GVHD) in both HLA-matched and -mismatched allogeneic stem-cell transplants, a randomized study showed.
The incidence of grade 3/4 acute GVHD after matched transplants decreased from 14.8% with standard prophylaxis to 6.8% with the addition of abatacept (Orencia). In a small group of patients who had 7/8-HLA-mismatched transplants, grade 3/4 acute GVHD at day 100 declined significantly from 30.2% with standard prophylaxis to 2.3% with add-on abatacept (
P 0.001).
Treatment with abatacept was not associated with increased rates of disease relapse or infection, investigators reported in the We found really striking results, particularly with those who were mismatched stem-cell transplants, in preventing acute GVHD, said Benjamin Watkins, MD, of Aflac Cancer and Blood Disorders Center and Emory University in Atlanta. This was a pretty rigorously run trial . and I think with thes
Spotlight on Scott Furlan
Scott Furlan, pediatric oncologist
Dr. Scott Furlan, a pediatric oncologist at Fred Hutchinson Cancer Research Center, believes he was drawn to bone marrow transplantation because of the sheer complexity of the challenge.
“In pediatric transplant, each patient has a dizzying array of complex problems, each of which often has multiple solutions” Furlan said.
To treat his young cancer patients, he has to sort through raft of possibilities and options, while helping parents navigate the frightful choices that lie ahead of them.
“In pediatrics, we have the opportunity to develop long-lasting relationships and extraordinary connections with patients and families. I still talk with many patients and their parents a decade later,” Furlan said.
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x109 cells per inf.
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium
January 18, 2021 01:00 ET | Source: Celyad Oncology SE Celyad Oncology SE Mont-Saint-Guibert, BELGIUM
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively
Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x10
9 cells per infusion
Emergence of new T cell clones in the peripheral blood T cell repertoire four months after therapy was observed in patients analyzed from the highest dose level who experienced either a confirmed partial response or stable disease suggesting that modulation of the endogenous immune response may be an important mechanism of action of CYAD